
Cambridge Healthtech Institute’s 2nd Annual
Advanced Diagnostics for Precision Oncology
Multi-Cancer Early Detection and Minimal Residual Disease Testing
March 7-8, 2023
Multi-cancer early detection and advanced cancer diagnostics promise to transform cancer treatment and save lives. Cambridge Healthtech Institute’s 2nd Annual Advanced Diagnostics for Precision Oncology meeting convenes key stakeholders
to discuss not only MCED and MRD emerging technologies, but also the business models, reimbursement and market access challenges, investment and partnering opportunities, and impact on the big pharma oncology models.
Coverage will include, but is not limited to:
- Minimal residual disease detection
- Multi-cancer early detection, advanced diagnostics, and population screening
- Business model and market access for early detection diagnostics
- Impact of early detection technologies on big pharma models
- Market access, regulatory, and reimbursement considerations for MCED
- Molecular characterization for targeted therapy selection
- Predictive and prognostic cancer biomarkers and companion diagnostics
- Integrating genomic and molecular testing into patient care
The deadline for priority consideration is July 29, 2022.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation:
For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com
For sponsorship information, please contact:
Jon Stroup
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5483
Email: jstroup@healthtech.com